Sever, O. N. Et Al. 2021. Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment.. Indian journal of cancer , vol.58 , 91-95.

Sever, O. N., Oktay, K., Güzel, E., Kaya, V., Güzel, A., & Yıldırım, M., (2021). Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment.. Indian journal of cancer , vol.58, 91-95.

Sever, Ozlem Et Al. "Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment.," Indian journal of cancer , vol.58, 91-95, 2021

Sever, Ozlem N. Et Al. "Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment.." Indian journal of cancer , vol.58, pp.91-95, 2021

Sever, O. N. Et Al. (2021) . "Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment.." Indian journal of cancer , vol.58, pp.91-95.

@article{article, author={Ozlem Nuray Sever Et Al. }, title={Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment.}, journal={Indian journal of cancer}, year=2021, pages={91-95} }